FAS-L Rabbit Polyclonal Antibody

This gene is a member of the tumor necrosis factor superfamily. The primary function of the encoded transmembrane protein is the induction of apoptosis triggered by binding to FAS. The FAS/FASLG signaling pathway is essential for immune system regulation, including activation-induced cell death (AICD) of T cells and cytotoxic T lymphocyte induced cell death. It has also been implicated in the progression of several cancers. Defects in this gene may be related to some cases of systemic lupus erythematosus (SLE) . Alternatively spliced transcript variants have been described. [provided by RefSeq, Nov 2014], disease:Defects in FASLG are the cause of autoimmune lymphoproliferative syndrome type 1B (ALPS1B) [MIM:601859]; also known as Canale-Smith syndrome (CSS) . ALPS is a childhood syndrome involving hemolytic anemia and thrombocytopenia with massive lymphadenopathy and splenomegaly., function:Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells. May be involved in cytotoxic T-cell mediated apoptosis and in T-cell development. TNFRSF6/FAS-mediated apoptosis may have a role in the induction of peripheral tolerance, in the antigen-stimulated suicide of mature T-cells, or both. Binding to the decoy receptor TNFRSF6B/DcR3 modulates its effects., online information:FAS-ligand entry, online information:FASLG mutation db, PTM:N-glycosylated., PTM:The soluble form derives from the membrane form by proteolytic processing., similarity:Belongs to the tumor necrosis factor family., subcellular location:May be released into the extracellular fluid, probably by cleavage form the cell surface., subunit:Homotrimer.

FASLG; APT1LG1; CD95L; FASL; TNFSF6; Tumor necrosis factor ligand superfamily member 6; Apoptosis antigen ligand; APTL; CD95 ligand; CD95-L; Fas antigen ligand; Fas ligand; FasL; CD antigen CD178

MAPK_ERK_Growth; MAPK_G_Protein; Cytokine-cytokine receptor interaction; Apoptosis_Inhibition; Apoptosis_Mitochondrial; Apoptosis_Overview; Natural killer cell mediated cytotoxicity; Neurotrophin; Type I diabetes mellitus; Pathways in cancer; Autoimmune thyroid disease; Allograft rejection; Graft-versus-host disease